| Autor: |
Sebastian Brandner, Ningning Li, Andreas von Deimling, Lei Wang, Sheng Chen, Jasper deBoer, Angela Richard-Loendt, Francesca Launchbury, Natasha Aley, Tedani El-Hassan, Joanne Lau, Matthew Ellis, Kastytis Sidlauskas, James Innes, Stefan Pusch, Ying Zhang |
| Rok vydání: |
2023 |
| DOI: |
10.1158/0008-5472.c.6510776.v1 |
| Popis: |
Human astrocytomas and oligodendrogliomas are defined by mutations of the metabolic enzymes isocitrate dehydrogenase (IDH) 1 or 2, resulting in the production of the abnormal metabolite D-2 hydroxyglutarate. Here, we studied the effect of mutant IDH on cell proliferation and apoptosis in a glioma mouse model. Tumors were generated by inactivating Pten and p53 in forebrain progenitors and compared with tumors additionally expressing the Idh1 R132H mutation. Idh-mutant cells proliferated less in vitro and mice with Idh-mutant tumors survived significantly longer compared with Idh-wildtype mice. Comparison of miRNA and RNA expression profiles of Idh-wildtype and Idh-mutant cells and tumors revealed miR-183 was significantly upregulated in IDH-mutant cells. Idh-mutant cells were more sensitive to endoplasmic reticulum (ER) stress, resulting in increased apoptosis and thus reduced cell proliferation and survival. This was mediated by the interaction of miR-183 with the 5′ untranslated region of semaphorin 3E, downregulating its function as an apoptosis suppressor. In conclusion, we show that mutant Idh1 delays tumorigenesis and sensitizes tumor cells to ER stress and apoptosis. This may open opportunities for drug treatments targeting the miR-183–semaphorin axis.Significance:The pathologic metabolite 2-hydroxyglutarate, generated by IDH-mutant astrocytomas, sensitizes tumor cells to ER stress and delays tumorigenesis. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
